JIKEI HEART STUDY PDF

Valsartan in a Japanese population with hypertension and other cardiovascular disease Jikei Heart Study : a randomised, open-label, blinded endpoint morbidity-mortality study. Retraction in Lancet. Comment in Lancet. J Clin Hypertens Greenwich. However, evidence for this effect in Asian populations is scarce.

Author:Shaktizragore Mooguran
Country:United Arab Emirates
Language:English (Spanish)
Genre:Art
Published (Last):6 March 2013
Pages:435
PDF File Size:2.79 Mb
ePub File Size:5.68 Mb
ISBN:676-7-81233-243-2
Downloads:17670
Price:Free* [*Free Regsitration Required]
Uploader:Gozragore



Valsartan in a Japanese population with hypertension and other cardiovascular disease Jikei Heart Study : a randomised, open-label, blinded endpoint morbidity-mortality study. Retraction in Lancet. Comment in Lancet. J Clin Hypertens Greenwich. However, evidence for this effect in Asian populations is scarce. We aimed to investigate whether addition of an angiotensin receptor blocker, valsartan, to conventional cardiovascular treatment was effective in Japanese patients with cardiovascular disease.

METHODS: We initiated a multicentre, prospective, randomised controlled trial of Japanese patients, aged years, mean 65 [SD 10] years who were undergoing conventional treatment for hypertension, coronary heart disease, heart failure, or a combination of these disorders.

In addition to conventional treatment, patients were assigned either to valsartan mg per day or to other treatment without angiotensin receptor blockers. Our primary endpoint was a composite of cardiovascular morbidity and mortality. Analysis was by intention to treat.

The study was registered at clintrials. This difference was mainly attributable to fewer incidences of stroke and transient ischaemic attack 29 vs 48; 0. Mortality or tolerability did not differ between groups. These benefits cannot be entirely explained by a difference in blood pressure control.

BTS409L1 PDF

Retraction of the Jikei Heart Study

Zulkilrajas The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin II receptor blocker, in addition to conventional treatment, will improve the prognosis of Japanese patients with cardiovascular diseases hypertension, ischemic heart disease, congestive heart failure. Leave a Reply Cancel reply Your email address stufy not be published. Although we were initially satisfied with their response, in we published a letter from Dr Yui reporting further concerns. By using this form you agree with the storage and handling heqrt your data by this website per the terms of our privacy policy: Matsubara is not an author on the Jikei study. Another outrageous and potentiall quite dangerous violoation of medical, scientific, and human ethics by Big Pharma trying hearg sell their products. Larry Husten, at Cardiobrief, has jieki following the story in detail, and notes that the saga began with questions about papers by Hiroaki Matsubarawho now has eight retractions.

ELRIC D20 PDF

JIKEI HEART STUDY PDF

ARBs including valsartan were not permitted in the usual care group, but other medications were at the discretion of the investigator. Patients were stratified by presenting syndrome heart failure, ischemic heart disease, or hypertension. Principal Findings: Mean baseline systolic blood pressure was mm Hg. The trial was discontinued early at the recommendation of the Data Safety Monitoring Committee due to evidence of benefit. Blood pressure at follow-up was reduced by 8.

Related Articles